24 December 2025
Author: Upasana Sonigra
As 2025 draws to a close, we want to invite you in to see what we’ve been working on this year. In short, a lot has changed – but every change has been driven by one clear purpose: to support global scientific risk assessments and, ultimately, to have a positive impact on human health.
2025 has been a year of meaningful progress, strong partnerships, and key milestones. It has also been a year in which we have expanded our ability to help more organisations worldwide navigate scientific and regulatory environments with confidence.
Strengthening our capability to better support you
One of the most significant milestones of the year was welcoming Spektra Consultoria into Consult Lhasa. This integration has strengthened our capability and the scope of expertise available to our global scientific community. Together, we are better equipped to support risk assessments and help organisations navigate regulatory expectations with clarity and assurance.
As our team has grown, so has our knowledge and contribution to science.
Our consultants continue to stay at the forefront of their fields and share knowledge widely, ensuring the insights we provide are grounded in current thinking, credible science, and practical experience.
Growth, delivery, and new services
This has also been a year of clear operational growth. To meet increasing demand, the Consult Lhasa team expanded by around 60%, giving us greater scientific depth, broader expertise, and the resilience needed to support complex and time-critical work.
To meet your needs, we have scaled up our resources significantly, and that team growth translates directly into results for you. In 2025, we delivered twice as many projects as we did in 2024!
Alongside this, we launched our Extractables & Leachables (E&L) consulting service in direct response to evolving industry needs and the increasing importance of defensible, science-based justification in this area.
Aligned with the principles set out in the ICH Q3E draft guidance, our E&L consulting service supports a robust, science-based justification throughout the E&L lifecycle. From study design through interpretation, our service helps you build confident, defensible assessments for container closure systems and manufacturing processes.
Staying connected with our global community
Engagement with the community has been at the heart of 2025. This year, our consultants attended key international conferences, including SOT, SOS, Eurotox, and ACT, connecting with scientists, industry partners, and regulators to understand current pressures, challenges, and opportunities across the sector to better help our clients.
It was great to meet so many of you there and hear about your scientific problems.
Alongside our Lhasa Limited colleagues, we were proud to participate in the Lhasa symposia in Brazil, Mexico, China, South Korea, and India, creating space for regional discussion, real-world scientific challenges, and shared learning.
In addition, our consultants featured in 13 specialist Lhasa webinars throughout 2025, sharing practical insights on topics that matter to the community. Below is a selection of webinars our colleagues presented on:
- Nitrosoureas and beyond: What to do when the CPCA doesn’t apply. Lead Scientific Consultant David Ponting and Chief Scientific Officer Natan Segretti delivered an exploratory webinar on the updated EMA guidelines for nitrosourea risk assessment.
- Nitrosamine control: Real-world applications of ICH M7 Options 3 & 4. Drawing on real-world case studies from the paper “Industrial Case Studies Demonstrating Applicability of ICH M7 Control Options 3 and 4 for Nitrosamine Control,” Scientific Consultant, Michael Burns, along with the other authors, presented evidence-based strategies to justify process-driven control strategies (Option 4) and hybrid approaches (Option 3) for these high-potency impurities.
The evolving role of in silico tools in genotoxicity assessments Scientific Consultant Rob Foster, alongside an expert industry panel, explored how computational tools support assessment of chromosome damage. We heard from a regulator, an agrochemical industry professional and a scientist on how in silico models are shaping the future of genotoxicity risk assessment.
Alongside webinars, we also continued to share thinking through the Consult Lhasa blog, reflecting real questions and challenges raised by organisations we support.
Recent titles include:
- Ten considerations for scientifically robust and defensible nitrosamine safety risk assessments
- Five tips for a cost-efficient, compliant control strategy
- A structured approach for non-mutagenic impurity qualification
With a global team providing support in more than 7 languages, we continue to ensure that meaningful, expert conversations are possible regardless of geography.
- If you would like to know more about our events, sign up for our newsletter
Powered by experience, guided by science
Behind this progress is a highly experienced consulting team. By the end of 2025, Consult Lhasa will collectively represent more than 323 years of scientific experience, with our scientific consultants contributing to over 238 publications.
Our Lhasa DNA means we understand the science, the regulations and what success really looks like for you.
Our scientific consultants helped develop the Lhasa Limited solutions used globally today. This gives us a deep understanding of the scientific logic behind them, the regulatory expectations they support, and the realities our clients face in practice. The result is advice that is not only technically robust, but practical, defensible, and ready to support real-world decision making.
Thank you, and looking ahead
The progress we’ve made this year reflects the strength of the organisations we partner with and the dedication of our global team. Thank you to everyone who has been part of our 2025 journey.
The momentum we’ve seen this year is a testament to collaboration, shared purpose, and the belief that better science leads to better outcomes for patients. We’re excited for what 2026 will bring.
As we move into 2026, we remain focused on supporting you with clarity, expertise, and meaningful partnership, whether in E&Ls, impurity assessment, or navigating new regulatory environments. We look forward to seeing what the new year will bring.
